800 Scudders Mill Rd
Tel: (609) 987-5800
About Novo Nordisk
Novo Nordisk is the world's leading diabetes care company and the only company that provides a complete portfolio of insulin analog treatments and insulin delivery devices that respond to each stage of the diabetes life cycle. In addition, Novo Nordisk has a leading position in hemostasis management, growth hormone therapy and hormone therapy for women.
Novo Nordisk's ambition is to defeat diabetes, working as a catalyst to advance diabetes care through awareness, prevention, and education and to be at the forefront of research and development in other areas of healthcare where it can make a significant difference.
Triple Bottom Line
Novo Nordisk conducts its activities in a financially, environmentally, and socially responsible way as part of its underlying business principle, The Triple Bottom Line. This principle is the foundation of the Novo Nordisk Way of Management, which holds Novo Nordisk to the highest performance standards.
Novo Nordisk Highlights
• A heritage in diabetes care for more than 80 years • World's largest makers of insulin • More than 4,600 employees are engaged in research and development • In 2005, spent DKK 5,085 million in R & D • Operates manufacturing facilities in six nations, including the United States • Operates three research and development facilities worldwide (Denmark, US, China) • Rated as a healthcare leader on the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index (global recognition) • Named number one best place to work among large companies in NJ by NJBIZ magazine
• Global headquarters in Copenhagen, Denmark • US headquarters in Princeton, NJ • Employs an estimated 27,000 people in 81 countries • Markets its products in 179 countries • Employs 3900 people in the US • Insulin manufacturing facility in Clayton, NC
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.
Total sales in 2008 were: $8,935 million (DKK 45,553m) Net income-as reported in 2008: $1,892 million (DKK 9,645m) Earnings per share-as reported: $3.07(DKK 15.66) Dividends paid per share: $1.18(DKK 6.00)
History of Novo Nordisk
In the 1920s, two small Danish companies began producing insulin, which had just been discovered by a team of Canadian scientists. Nordisk Insulin laboratorium was founded in 1923.
A year later, Novo Terapeutisk Laboratorium was born, and began producing "Insulin Novo" and a special syringe. Over the decades, these two companies grew to be global leaders in insulin production. In January 1989, Novo and Nordisk decided to join forces to form a new company called Novo Nordisk A/S.
Please click here for Novo Nordisk job opportunities.
Please click here for clinical trial information.
FOLLOW NOVO NORDISK:
Tweets by Novo Nordisk
1210 articles with Novo Nordisk
Diabeloop Announces Collaboration With Novo Nordisk to Pursue Its Interoperability Strategy With Connected Insulin Pens
Diabeloop, a pioneer in Automated Insulin Delivery, will collaborate with leading global healthcare company, Novo Nordisk.
After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.
Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024
Novo Nordisk Inc. today announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes.
Novo Nordisk announced Thursday it plans to expand its research and development operations in the greater Boston area and add over 200 new jobs this year.
Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes
The U.S. Food and Drug Administration has approved a label update for Rybelsus® tablets 7 mg or 14 mg, allowing use as a first-line treatment option for adults with type 2 diabetes who have not previously taken a diabetes treatment.
Amalgam Rx™ Enhances Partnership with Novo Nordisk®
Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the expansion of its global agreement with Novo Nordisk for the commercialization of Dose Check.
Seven pharma CEOs announce new joint action to accelerate net zero healthcare
CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor
BIOCORP announces the signature of a partnership agreement with Novo Nordisk for the commercialization of Mallya, initially in Japan.
Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program
Ventus Therapeutics, Inc. announced that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.
Novo Nordisk struck a licensing deal Thursday with Ventus Therapeutics valued at up to $700 million to develop and commercialize peripherally-restricted NLRP3 inhibitors.
This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.
New data from Novo Nordisk's Phase IIIa ONWARD 2 trial studying insulin icodec shows it is effective as a once-weekly treatment for Type 2 diabetes.
Novo Nordisk and Octagon Therapeutics announced that they forged a research collaboration focused on inflammatory diseases.
Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk
Octagon Therapeutics today announced the initiation of a research collaboration with Novo Nordisk focused on inflammatory disease.
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® for injection.
Investigational 2.0mg Semaglutide Dose Promoted for Type 2 Diabetics With Higher A1c ScoreOzempics Continuing to Stand Out as a New Type 2 Diabetes Medication Alternative
Novo Nordisk introduced Ozempic to the market in 2017, giving Type 2 diabetics a different option when it comes to their injections made for keeping their blood sugar levels down and managing their diabetes effectively.
Novo Nordisk has entered into an agreement to acquire Forma Therapeutics for $1.1 billion. Forma’s lead development candidate, etavopivat, is being developed for sickle cell disease.
A combination of Novo Nordisk's CagriSema injection for overweight people with type II diabetes resulted in a 15.6% body weight reduction compared to taking the drugs individually.
As the world faces one public health crisis after another, it seems that pharmaceutical companies across the board are having trouble keeping up with the ever-growing need for medicines.
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.